With over 20 years of experience in oligonucleotide development and production, and over 1000 sequences manufactured, Avecia has played an integral role in the advancing oligo therapeutic market. Their mission is to continue to build value for their customers, as they progress through drug development into commercialization. And as a member of the Nitto Denko Corporation (www.nitto.com), Avecia is committed to the future of the oligonucleotide market. They are driven by innovative ideas and flexible solutions, designed to provide their customers with the best in service, quality, and technology.
Their FDA inspected facilities in Milford, MA and Cincinnati, OH are aligned to the needs of the pre-clinical, clinical, and launched product oligonucleotide markets. Their aim is to leverage their wealth of experience, and their understanding of the regulatory needs in each of these segments, to ensure they exceed their customer’s expectations.
Their Cincinnati, OH location provides distinct advantages to their customers, including security of supply; Avecia is pleased to offer their customers CGMP large scale oligo manufacturing capacity in two separate facilities. Their Cincinnati facility also provides additional pre-clinical oligo manufacturing services.
Their portfolio of services includes process and analytical development, pre-clinical and CGMP oligo manufacture, and quality control testing, including on site ICH stability storage and testing. All of their customers benefit from their experienced supply chain team, as well as a quality team ready to manage the regulatory needs of projects at all phases of development.See more